Good morning. Happy New Year! Today’s CFOs are expected not only to own the numbers, but also to act as core strategists, digital leaders, and enterprise change agents. I recently talked about this topic with Robinhood CFO Jason Warnick and his successor, Shiv Verma, SVP of finance and strategy and treasurer. At Robinhood, the Menlo Park, Calif.–based fintech and asset trading platform, Verma is stepping into the top finance job. Warnick is retiring and moving into an advisory role this quarter, remaining w ...

Core Insights - Beyond Air, Inc. has appointed Dan Moorhead as Chief Financial Officer, effective January 5, 2026, succeeding Duke Dewrell, who served as interim CFO since November 2025 [1][2] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on utilizing nitric oxide (NO) to enhance patient care, particularly for respiratory illnesses, neurological disorders, and solid tumors [5][6] - The company has received FDA approval and CE Mark for its first system, LungFit PH, aimed at treating term and near-term neonates with hypoxic respiratory failure [5] Leadership Appointment - Dan Moorhead brings over 20 years of finance leadership experience, having previously served as CFO of Zynex, Inc., where he supported significant commercial expansion [3] - Moorhead expressed enthusiasm about joining Beyond Air at a critical time, particularly with the upcoming FDA approval of the second generation LungFit PH and its commercial launch [2][3] Inducement Stock Option - Upon his appointment, Moorhead was granted an inducement stock option for 70,000 shares of the company's common stock, exercisable at the last reported sale price on December 31, 2025 [4] - The stock option has a ten-year term and will vest over four years, with 25% vesting on the first anniversary and the remainder in three equal installments [4] Product Development - Beyond Air is advancing its LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [5][6] - The company is also collaborating with The Hebrew University of Jerusalem on a pre-clinical program for treating autism spectrum disorder and other neurological disorders [6]

Distribution network coverage expanded to a total of 39 countriesGARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network to include Germany, Brazil, Austria, the Netherland ...

As filed with the Securities and Exchange Commission on December 11, 2025 Registration No. 333-291699 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Beyond Air, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 47-3812456 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Numbe ...

Company Overview - DoorDash was founded in 2013 by Tony Xu and three fellow Stanford students and has become the clear market leader in the U.S. restaurant delivery sector, controlling approximately 60% of the market, which is more than double that of its closest competitor, Uber Eats [1][2]. Business Strategy - The company is expanding into new retail categories and geographies, utilizing in-house mapping technology to optimize delivery logistics, which provides a competitive edge in the delivery-app market [3]. - DoorDash aims to build a comprehensive catalog of the physical world, leveraging data that is not available on platforms like Google Maps or ChatGPT [4]. Leadership and Innovation - Tony Xu's leadership style is gaining attention from peers in the tech industry, including Meta CEO Mark Zuckerberg, highlighting his influence and strategic vision [4]. - The company has developed a highly efficient logistics engine powered by machine learning, which has been in place for the past decade [6]. AI and Data Utilization - DoorDash is strategically positioned to maintain its dominance in the AI-driven local commerce sector, supported by a vast proprietary dataset and a robust AI infrastructure designed for rapid iteration [7]. - The company integrates AI across all operations, enhancing its service delivery and operational efficiency [7]. Financial Performance - DoorDash has seen significant growth, ranking No. 394 on the Fortune 500 list, having debuted at No. 443 in 2024 [6].

Group 1 - Chagee Holdings Ltd. (NASDAQ:CHA) is expected to report quarterly earnings of 40 cents per share on revenue of $458.31 million [2] - Tilray Brands Inc. (NASDAQ:TLRY) announced a 1-for-10 reverse stock split, resulting in a 16% decline in shares to $0.86 in after-hours trading [2] - Analysts predict Globus Maritime Ltd. (NASDAQ:GLBS) will post a quarterly loss of 12 cents per share on revenue of $10.50 million, with shares rising 1.5% to $1.36 in after-hours trading [2] - Post Holdings Inc. (NYSE:POST) has authorized a $500 million share buyback program, leading to a 1.8% increase in shares to close at $102.82 [2] - Beyond Air Inc. (NASDAQ:XAIR) announced the resignation of CFO Doug Larson and appointed Duke Drewell as interim CFO, with shares rising 1.5% to $1.35 in after-hours trading [2]

Core Points - Doug Larson has resigned as Chief Financial Officer of Beyond Air, Inc. to pursue another opportunity, with an interim CFO to be appointed [1][4] - Larson's leadership was crucial in transitioning Beyond Air to a commercial business, particularly with the launch of LungFit PH and clinical research subsidiaries [2] - Beyond Air is actively searching for a permanent successor for the CFO position [1] Company Overview - Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on using nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors [5] - The company has received FDA approval and CE Mark for its LungFit PH system, aimed at treating neonates with hypoxic respiratory failure [5][9] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including COVID-19 [5][8] Product Details - LungFit is a cylinder-free, phasic flow generator that delivers nitric oxide at concentrations from 1 ppm to 80 ppm, offering operational advantages in hospital settings [7] - The system is designed to replace high-pressure nitric oxide cylinders, improving safety and reducing storage requirements [7] - Beyond Air aims to provide nitric oxide treatment in home settings, particularly for chronic lung infections [8] Research and Development - Beyond Air has partnered with The Hebrew University of Jerusalem to develop treatments for autism spectrum disorder and other neurological disorders [6] - Beyond Cancer, an affiliate of Beyond Air, is investigating the use of ultra-high concentrations of nitric oxide for targeting solid tumors [12] - NeuroNOS, another affiliate, focuses on therapies for neurodevelopmental and neurodegenerative disorders by regulating nitric oxide levels in the brain [13]

Washington, D.C. 20549 _________________________________ As filed with the Securities and Exchange Commission on November 21, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 _________________________________ Beyond Air, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3841 47-38 ...

Revenue Performance - Revenue increased by 128% year over year to $1.8 million for the fiscal quarter ended September 30, 2025, compared to $0.8 million for the same period last year[8] - Revenues for the three months ended September 30, 2025, were $1,818,000, compared to $798,000 for the same period in 2024, representing a 128% increase[32] - Updated fiscal year 2026 revenue guidance to $8 - $10 million[19] Expenses and Losses - Gross loss decreased to $0.3 million for the quarter ended September 30, 2025, compared to a gross loss of $1.1 million for the same period last year[11] - Research and development expenses decreased to $2.5 million for the quarter ended September 30, 2025, from $4.6 million for the same period last year[12] - Selling, general and administrative expenses decreased to $4.9 million for the quarter ended September 30, 2025, compared to $7.2 million for the same period last year[13] - Net loss attributed to common stockholders was ($7.9) million or a loss of ($1.25) per share for the quarter ended September 30, 2025, compared to a net loss of ($13.4) million or ($5.67) per share for the same period last year[15] - The net loss attributable to Beyond Air, Inc. for the three months ended September 30, 2025, was $7,940,000, compared to $13,358,000 for the same period in 2024, reflecting a 41% decrease[32] Cash and Assets - Proforma cash, cash equivalents, restricted cash, and marketable securities totaled $22.9 million as of September 30, 2025[1] - Cash and cash equivalents increased to $9,699,000 as of September 30, 2025, from $4,665,000 as of March 31, 2025[33] - Total assets as of September 30, 2025, were $30,965,000, compared to $30,062,000 as of March 31, 2025, showing a growth of 3%[33] Operating Expenses - Total operating expenses for the three months ended September 30, 2025, were $7,363,000, down from $11,748,000 in the same period of 2024, indicating a 37% reduction[32] - Research and development expenses for the six months ended September 30, 2025, were $5,536,000, down from $10,594,000 in the same period of 2024, a reduction of 48%[32] Distribution and Designation - The company expanded its global LungFit PH distribution network to 35 countries, covering a combined population of 2.8 billion people[8] - The U.S. FDA granted Orphan Drug Designation to investigational therapies BA-101 and BA-102 for the treatment of Glioblastoma and Phelan-McDermid Syndrome, respectively[16] Other Financial Metrics - Net cash burn for the quarter ended September 30, 2025, was $4.7 million[17] - The weighted average number of shares outstanding for the three months ended September 30, 2025, was 6,356,573, compared to 2,355,927 for the same period in 2024, indicating a significant increase in shares[32] - The total liabilities as of September 30, 2025, were $17,870,000, an increase from $15,721,000 as of March 31, 2025[33] - The company reported a foreign currency translation loss of $18,000 for the three months ended September 30, 2025[32]

Financial Data and Key Metrics Changes - Revenue for the fiscal second quarter increased by 128% year-over-year, reaching $1.8 million, up from $0.8 million in the same period last year [4][15] - The company reported a gross loss of $0.3 million for the fiscal second quarter, an improvement from a loss of $1.1 million for the same period last year [16] - Net loss attributed to common stockholders was $7.9 million, or a loss of $1.25 per share, compared to a net loss of $13.4 million, or a loss of $5.67 per share, for the same quarter last year [18] Business Line Data and Key Metrics Changes - The company introduced a capital purchase sales model in the U.S. and had its first hospital purchase of LungFit PH [6] - The sales pipeline remains robust, with substantial opportunities across the U.S. as awareness of LungFit PH builds [4] Market Data and Key Metrics Changes - The company added new distribution partnerships in Japan, South Korea, Mexico, Costa Rica, Guatemala, Panama, and El Salvador, expanding its international coverage to 35 countries [10][11] - The company anticipates reaching its goal of 60 countries under partnership by calendar 2026 [11] Company Strategy and Development Direction - The company is preparing for the launch of its second-generation LungFit system, expected in late calendar 2026, pending FDA approval [8] - A national group purchasing agreement for therapeutic gases with Premier has been awarded, providing access to nearly 3,000 hospitals [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the trajectory of growth post-launch of the second-generation LungFit PH, anticipating a steeper growth curve [23] - The company is navigating complexities in hospital sales cycles, with expectations for sequential growth to resume in upcoming quarters [4] Other Important Information - The company raised $12 million in debt and plans to file a registration statement for an additional $20 million through an equity line of credit [5] - The company reported a 37% reduction in total operating expenses year-over-year, down to just above $7.4 million from $11.7 million [16] Q&A Session Summary Question: Expected growth drivers leading into the potential approval of the second-generation LungFit PH - Management believes the trajectory post-launch will be significantly steeper, with international expansion and the introduction of a capital purchase model as key growth drivers [23][24] Question: Comments on timing for commercialization of the second-gen LungFit PH - Management indicated that FDA timing is not the limiting factor, but supply chain issues are affecting the timeline [26] Question: Comparison between the new model and prior ones - The second-generation machine will be about 60% the size of the original, with improved user interface and longer maintenance intervals [28][29] Question: Insights on international deals and pricing models - The international model involves selling to distributors who then use various models, including capital equipment purchases and disposables [33] Question: Update on the updated guidance of $8 million-$10 million - Management noted that the transition in leadership may cause some disruption, but the revenue target is achievable based on current performance [35][36]